Quantcast
Home > Quotes > ARNA
ARNA

Arena Pharmaceuticals, Inc. Common Stock (ARNA) Quote & Summary Data

$40.86
*  
0.82
1.97%
Get ARNA Alerts
*Delayed - data as of Nov. 19, 2018  -  Find a broker to begin trading ARNA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ARNA Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
62.5
Today's High / Low
$ 42.31 / $ 40.0301
Share Volume
746,021
50 Day Avg. Daily Volume
661,647
Previous Close
$ 41.68
52 Week High / Low
$ 50.05 / $ 26.2534
Market Cap
2,018,747,629
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.50
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.04

Intraday Chart

Shares Traded

Share Volume:
746,021
50 Day Avg. Daily Volume:
661,647

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.50

Trading Range

The current last sale of $40.86 is 55.64% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 42.31 $ 50.05
 Low: $ 40.0301 $ 26.2534

ETFs with ARNA as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
2.62% Virtus LifeSci Biotech Clinical Trials ETF (BBC) -6.21 (-19.21%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver clinical utility across therapeutic areas. Our proprietary, internally-developed pipeline includes multiple potentially first- or best-in-class programs. Our three most advanced investigational clinical programs are: ralinepag (APD811), which we are currently preparing for a Phase 3 program for pulmonary arterial hypertension, or PAH; etrasimod (APD334), which is being studied in Phase 2 trials for immune and inflammatory conditions with an initial focus on ulcerative colitis and hepatic conditions; and APD371 for visceral pain conditions and which is being studied in a Phase 2 trial for treatment of pain associated with Crohn's disease, or CD.  ... More ...  


Risk Grade

Where does ARNA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 41.89
Open Date:
Nov. 19, 2018
Close Price:
$ 40.86
Close Date:
Nov. 19, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x